Acute inhibition of AMPA receptors by perampanel reduces amyloid β‐protein levels by suppressing β‐cleavage of APP in Alzheimer's disease models
Authors:
- Sakiho UedaSUSakiho Ueda
- Akira KuzuyaAKAkira Kuzuya
- Masayoshi KawataMKMasayoshi Kawata
- Kohei OkawaKOKohei Okawa
- Chika HonjoCHChika Honjo
- Takafumi WadaTWTakafumi Wada
- Mizuki MatsumotoMMMizuki Matsumoto
- Kazuya GotoKGKazuya Goto
- Masakazu MiyamotoMMMasakazu Miyamoto
- Atsushi YonezawaAYAtsushi Yonezawa
- Yasuto TanabeYTYasuto Tanabe
- Akio IkedaAIAkio Ikeda
Open Access
- 18 October 2023
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 37 (11) , e23252
Abstract
Hippocampal hyperexcitability is a promising therapeutic target to prevent Aβ deposition in AD since enhanced neuronal activity promotes presynaptic Aβ production and release. This article highlights the potential application of perampanel (PER), an AMPA receptor (AMPAR) antagonist approved for partial seizures, as a therapeutic agent for AD. Using transgenic AD mice combined with in vivo brain microdialysis and primary neurons under oligomeric Aβ‐evoked neuronal hyperexcitability, the acute effects of PER on Aβ metabolism were investigated. A single oral administration of PER rapidly decreased ISF Aβ 40 and Aβ 42 levels in the hippocampus of J20, APP transgenic mice, without affecting the Aβ 40 /Aβ 42 ratio; 5 mg/kg PER resulted in declines of 20% and 31%, respectively. Moreover, PER‐treated J20 manifested a marked decrease in hippocampal APP βCTF levels with increased FL‐APP levels. Consistently, acute treatment of PER reduced sAPPβ levels, a direct byproduct of β‐cleavage of APP, released to the medium in primary neuronal cultures under oligomeric Aβ‐induced neuronal hyperexcitability. To further evaluate the effect of PER on ISF Aβ clearance, a γ‐secretase inhibitor was administered to J20 1 h after PER treatment. PER did not influence the elimination of ISF Aβ, indicating that the acute effect of PER is predominantly on Aβ production. In conclusion, acute treatment of PER reduces Aβ production by suppressing β‐cleavage of amyloid‐β precursor protein effectively, indicating a potential effect of PER against Aβ pathology in AD.Keywords
Funding Information
- Japan Society for the Promotion of Science (JP21K20690, JP20K07884)
This publication has 92 references indexed in Scilit:
- Neuroinflammation and Neuronal Loss Precede Aβ Plaque Deposition in the hAPP-J20 Mouse Model of Alzheimer’s DiseasePLOS ONE, 2013
- Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease modelProceedings of the National Academy of Sciences, 2012
- Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s diseaseProceedings of the National Academy of Sciences, 2012
- Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive ImpairmentNeuron, 2012
- Neuronal activity regulates the regional vulnerability to amyloid-β depositionNature Neuroscience, 2011
- Inhibition of Calcineurin-mediated Endocytosis and α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptors Prevents Amyloid β Oligomer-induced Synaptic DisruptionJournal of Biological Chemistry, 2010
- Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive ImpairmentNeuropsychopharmacology, 2009
- The Effects of Amyloid Precursor Protein on Postsynaptic Composition and ActivityJournal of Biological Chemistry, 2009
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In VivoNeuron, 2008